Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyProvidence SCIT Policy Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy 448

    Allergen Subcutaneous Immunotherapy (SCIT)

    Customize your policy alerts

    Sign up for Providence Health Plan Policy 448 alerts

    Get alerted when Policy 448 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage criteria, documentation, limitations, and medical necessity for office-, facility-, and exceptionally home-based allergen SCIT, including rapid desensitization, for applicable Providence commercial products and related Providence entities. Oral or nasal allergy immunotherapy and food allergy treatments are excluded.

    Policy Summary
    PayerProvidence Health Plan
    PolicyAllergen Subcutaneous Immunotherapy (SCIT)
    Policy CodePolicy 448
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNov 1, 2027
    Key ActionSubmit pertinent medical records and chart notes with the request so medical necessity can be determined.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    150 unitsCPT 95165 rolling 12-month limit
    3Rapid desensitization qualifying pathways
    Rare exceptionsHome administration
    7Home administration safeguards
    30 minutesPost-injection observation

    Medical Necessity and Coverage Criteria

    Office- or facility-based SCIT

    Office- or facility-based SCIT may be considered medically necessary when ALL of the following criteria are met:

    • IgE-mediated allergy: The allergy is IgE-mediated, as documented by skin testing or RAST.
    • Inadequate medication control: Symptoms are not easily controlled with medication.
    • Multiseason symptoms: Symptoms encompass more than one season.more than one season
    • Qualified ordering provider: Therapy is ordered by a healthcare provider licensed and trained in allergy immunotherapy.

    Home-based SCIT

    Home-based SCIT may be considered medically necessary only on an individual basis after case review and when the documented exception requirements are met:

    Home-based SCIT exception

    • Need documented: Adequate documentation explains why home administration is needed.
    • Reaction-response training: The member or an adult household member is trained to recognize and treat anaphylactic and/or allergic reactions to immunotherapy administration.
    • Epinephrine available: Epinephrine kits are available, and the member or adult household member is instructed in their use.
    • Administration training: The member or adult household member is trained in the antigen dosing plan, withdrawal of the correct amount of antigen from the vial, and administration of SCIT.

    Rapid desensitization

    Rapid desensitization may be considered medically necessary when ANY ONE of the following qualifying indications is met:

    Rapid desensitization indications

    • Drug allergy: The member has an allergy to a particular drug for a condition that cannot be treated effectively with alternative medications.
    • Hymenoptera hypersensitivity: The member has insect-sting hypersensitivity involving wasps, hornets, bees, fire ants, or other Hymenoptera.
    • Seasonal allergic rhinitis: The member has moderate-to-severe allergic rhinitis requiring treatment during or immediately before the season of the affecting allergy, and avoidance or pharmacotherapy failed to control symptoms.moderate to severe

    Exceptional home immunotherapy

    Home immunotherapy may be considered only when ALL core conditions and documentation requirements are met:

    Exceptional home administration

    • Required home-administration safeguards

      • Documentation requirements: Document why home administration is needed; training to recognize and treat anaphylactic and/or allergic reactions; epinephrine availability and instruction in its use; training on the dosing plan, withdrawal of the correct antigen amount, and administration; signed consent; provider initiation of immunotherapy in the office with only continuation therapy at home; and signed acknowledgment of receipt of antigen vials under the individualized treatment protocol.

    Standard SCIT administration setting

    Standard administration and safety expectations:

    Office-based administration: Allergen immunotherapy should be administered in a medical office or facility with trained staff and medical equipment capable of recognizing and treating anaphylaxis.

    Safety practice parameters reinforce a 30-minute post-injection observation period and careful assessment of asthma control before administration.

    This policy addresses subcutaneous allergen immunotherapy (SCIT) and does not address allergy immunotherapy administered through oral or nasal routes, including Oralair®, Grastek®, Ragwitek®, and Odactra®. Food allergy treatments, including Palforzia®, are also outside the scope of this policy.

    Home-based rapid desensitization is considered not medically necessary.

    Frequent or routine home immunotherapy is not appropriate under any circumstances. SCIT should ordinarily be administered in a medical office or facility with trained staff and equipment capable of recognizing and treating anaphylaxis.

    Injection-only codes, including CPT 95115 and 95117, must not be used when the antigen is self-administered by the member.

    Component injection and antigen services are bundled when reported with comprehensive SCIT service codes CPT 95120–95134. Report either the applicable comprehensive service or the appropriate combination of injection and antigen services, as supported by the services actually rendered.

    Office- or facility-based SCIT is considered not medically necessary when all required criteria are not met. The allergy must be IgE-mediated and documented by skin testing or RAST, symptoms must not be easily controlled with medication, symptoms must encompass more than one season, and therapy must be ordered by a healthcare provider licensed and trained in allergy immunotherapy.

    Home-based SCIT is considered not medically necessary without an individual exception after case review. An exception requires documentation that facility administration is not feasible and that withholding therapy would seriously detriment the member’s health, along with the required home-administration safeguards and training.

    Rapid desensitization is considered not medically necessary unless at least one qualifying indication is documented: allergy to a particular drug for which alternative medication is ineffective, Hymenoptera insect-sting hypersensitivity, or moderate-to-severe allergic rhinitis requiring treatment during or immediately before the relevant season after avoidance or pharmacotherapy failed to control symptoms.

    Utilization of CPT 95165 exceeding 150 units per rolling 12 months is considered not medically necessary.

    Covered Services and Billing Codes

    Rapid DesensitizationCPTCovered
    95180Rapid desensitization (also known as rush, cluster, or acute desensitization)
    SCIT Unit LimitationCPTCovered
    95165Allergen immunotherapy code subject to a limit of 150 units per rolling 12 months
    Complete service codesCPT
    95120Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single injection.
    95121Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 or more injections.
    95122Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single stinging insect venom.
    95123Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 stinging insect venoms.
    95124Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 3 stinging insect venoms.
    95125Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 or more injections.
    95126Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract.
    95127Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract.
    95128Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract.
    95129Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract.
    1–10 of 15
    1/2
    Injection-only codesCPT
    95115Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection.
    95117Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections.
    Antigen preparation and provision codesCPT
    95144Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single dose vial(s) (specify number of vials).
    95145Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom.
    95146Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 2 single stinging insect venoms.
    95147Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 3 single stinging insect venoms.
    95148Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 4 single stinging insect venoms.
    95149Professional services for the supervision and provision of antigens for allergen immunotherapy (specify number of doses); 5 single stinging insect venom.
    95165Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses).
    95170Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; whole body extract of biting insect or other arthropod (specify number of doses).
    Rapid desensitizationCPT
    95180Rapid desensitization procedure, each hour (eg, insulin, penicillin, equine serum).
    Unlisted allergy/clinical immunologic service or procedureHCPCS
    95199Unlisted allergy/clinical immunologic service or procedure.
    CPT CodesCPT
    95125Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 or more injections.
    95130Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single stinging insect venom.
    95131Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 stinging insect venoms.
    95132Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 3 stinging insect venoms.
    95133Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 4 stinging insect venoms.
    95134Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 5 stinging insect venoms.
    95144Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single dose vial(s) (specify number of vials).
    95145Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom.
    95146Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 2 single stinging insect venoms.
    95147Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 3 single stinging insect venoms.
    1–10 of 15
    1/2
    HCPCS CodeHCPCS
    95199Unlisted allergy/clinical immunologic service or procedure.
    CPT 95165 Utilization Limit
    CodeCPT 95165
    Utilization limit150 units per rolling 12 months
    Excess utilizationUtilization exceeding the limit is not medically necessary

    Documentation, Authorization, and Denial Risks

    Documentation Required

    Submit Records With the Request

    Submit all records and chart notes pertinent to the request when requesting review. Documentation is required for Providence Health Plan to determine medical necessity.

    • Provide pertinent medical records and chart notes with the request.
    Prior Authorization

    Prior Authorization for Potentially Covered Unlisted Services

    For potentially covered services billed with an unlisted code, obtain prior authorization when recommended to avoid post-service denial. Unlisted codes are reviewed at the claim level for coverage, medical necessity, correct coding, and pricing.

    • Prior authorization is recommended for unlisted codes associated with potentially covered services.
    • Claim-level review still applies.

    Clinical Background

    Subcutaneous allergen immunotherapy (SCIT) is an established treatment that introduces allergens beneath the skin in gradually increasing doses to reduce sensitivity to environmental allergens. It is commonly used for allergic rhinitis, allergic conjunctivitis, allergic asthma, and Hymenoptera sensitivity, typically after allergen avoidance and medication-based treatment are inadequate. Treatment generally progresses from a build-up phase to maintenance dosing and is ordinarily administered in a medically supervised setting because serious reactions, including anaphylaxis, can occur.

    Key Terms and Treatment Phases

    Subcutaneous Allergen Immunotherapy (SCIT)
    DefinitionAn established treatment that introduces allergen subcutaneously in gradually increasing doses to make a person less sensitive to allergens
    PurposeSCIT is designed to prevent or lessen an allergic reaction; it does not cure allergies
    Common usesAllergic rhinitis, allergic conjunctivitis, allergic asthma, and Hymenoptera (stinging insect) sensitivity
    Build-up Phase
    DefinitionThe initial SCIT phase in which very low allergen doses are gradually increased until an effective dose is reached
    Injection frequencyTypically 1 to 3 injections per week
    Policy Summary
    PayerProvidence Health Plan
    PolicyAllergen Subcutaneous Immunotherapy (SCIT)
    Policy CodePolicy 448
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNov 1, 2027
    Key ActionSubmit pertinent medical records and chart notes with the request so medical necessity can be determined.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered Services and Billing CodesDocumentation, Authorization, and Denial RisksClinical BackgroundKey Terms and Treatment Phases
  1. Signed consent: The member or adult household member signs consent to administer allergy immunotherapy at home.
  2. Office initiation: The provider initiated allergy immunotherapy in the office, and only continued therapy is planned for the member's home.
  3. Vial receipt acknowledgment: The member or adult household member signs acknowledgment of receiving antigen vials according to the individualized treatment protocol.
  4. Documentation Required

    Provide Medical Necessity Records

    Include pertinent medical necessity records and chart notes with the request, including the medical history, examination, diagnostic and allergy-testing results supporting treatment, and the documented treatment plan and dosage regimen.

    • Document the clinical basis for treatment and the applicable allergy testing.
    • Document the treatment plan, dosage regimen, and qualified prescribing provider.
    Documentation Required

    Support Codes Post-Service

    For post-service review, submit documentation supporting the specific code billed, including the number of venoms, number of vials, and other service details.

    • Support the code submitted with records describing the venoms, vials, doses, or other billed services.
    Documentation Required

    Document Home Administration Requirements

    Home administration requires documentation of the clinical rationale, training, and safety measures supporting at-home immunotherapy. Routine home immunotherapy is not appropriate; only rare and exceptional circumstances may qualify on an individual basis.

    • Document why facility administration is not feasible.
    • Document training to recognize and treat reactions, epinephrine availability and instruction, and competency with dosing and administration.
    Documentation Required

    Maintain Home Administration Records

    If home administration is approved, maintain the required records in addition to the general documentation requirements. The record must establish training, consent, office initiation, and receipt of antigen vials under the individualized protocol.

    • Include signed consent and acknowledgement of antigen-vial receipt.
    • Document that office-based immunotherapy was initiated and that only continued therapy is planned at home.
    • Record member or adult household-member training in reaction management, epinephrine use, dosing, vial withdrawal, and administration.
    Billing Rule

    Support Claim Units and Dates

    Support every claim with documentation showing that the reported units and codes are accurate, medically reasonable and necessary, and tied to the actual service date.

    • Document the units rendered and medical necessity.
    • Ensure the submitted code is correct and the date of service matches the date the service was performed.
    • Bill allergen preparation units on the preparation date rather than splitting them over subsequent days.
    Documentation Required

    Document the Exception Rationale

    When requesting an exception for home administration, explain why the therapy cannot be administered in a medical facility and why withholding it would seriously harm the patient. Individual consideration may be appropriate in rare circumstances such as remote residence, disability, advanced age, or high infection risk.

    • Provide a specific patient-centered rationale for why facility administration is not feasible.
    • Explain the potential serious detriment of withholding therapy.
    Denial Risk

    Office-Based SCIT Criteria Must Be Met

    Office- or facility-based SCIT is not medically necessary when all required criteria are not met.

    • IgE-mediated allergy documented by skin testing or RAST.
    • Symptoms are not easily controlled with medication.
    • Symptoms encompass more than one season.
    • Therapy is ordered by a provider licensed and trained in allergy immunotherapy.
    Denial Risk

    Unsupported Home Administration

    Home-based SCIT is not medically necessary absent an individual exception approved after case review. Routine home administration is not supported without the required exception rationale and documentation.

    • Do not bill home administration as routine therapy.
    • Document the rare and exceptional circumstance, safety preparation, training, consent, office initiation, and antigen-vial receipt.
    Denial Risk

    Rapid Desensitization Criteria Must Be Met

    Rapid desensitization is not medically necessary unless the member meets at least one qualifying indication. Home-based rapid desensitization is not medically necessary.

    • Drug allergy for a condition that cannot be effectively treated with alternatives.
    • Hymenoptera insect-sting hypersensitivity.
    • Moderate-to-severe allergic rhinitis requiring in-season or immediately pre-season treatment after avoidance or pharmacotherapy failed.
    Denial Risk

    Home-Based Rapid Desensitization Not Medically Necessary

    Home-based rapid desensitization is considered not medically necessary, including when rapid desensitization might otherwise meet a qualifying indication.

    • CPT 95180 may be considered only for qualifying rapid-desensitization indications in an appropriate setting.
    • Do not provide or bill rapid desensitization as home-based treatment.
    Denial Risk

    Annual Unit Limit Exceeded

    CPT 95165 is limited to 150 units during a rolling 12-month period. Units exceeding the limit are not medically necessary.

    • Track utilization over each rolling 12-month period.
    • Do not submit units beyond the 150-unit limit without recognizing the excess as subject to denial.
    Denial Risk

    Routine Home Immunotherapy Is Not Covered

    Routine or frequent home immunotherapy is not appropriate. Home administration may qualify only in rare and exceptional circumstances when facility administration is not feasible and withholding therapy would seriously harm the patient.

    • Examples include venom-induced anaphylaxis in a remote region, advanced age or disability, rural residence, or immunocompromised status/high infection risk.
    • Use the required exception documentation and safety safeguards.
    Denial Risk

    Unsupported Units or Incorrect Dates

    Claims may be denied when units are unsupported, codes are incorrect, medical necessity is not established, or the claim date does not match the actual date of service.

    • Ensure records support the units rendered and the services' medical necessity.
    • Report the actual service date; do not distribute services from one date across claims using different dates.
    • Bill allergen preparation on the preparation date.
    Billing Rule

    Self-Administered Injection Coding

    Do not report injection-only codes when the antigen is self-administered by the member. CPT 95115 and 95117 are for professional administration and do not include antigen or its preparation.

    • Injection-only codes may be used when a different physician performs the injection or when the injection is professionally administered.
    • Select codes that accurately represent the service rendered and are supported by the medical record.
    Billing Rule

    Bundled Component Services

    Component services reported with comprehensive SCIT codes are denied as bundled. Use either the complete service codes or the appropriate combination of injection and antigen/ preparation codes, consistent with the services rendered.

    • CPT 95115-95117 and 95144-95170 deny as bundled when reported with CPT 95120-95134.
    • CPT 95165 units are based on 1-cc doses in the vial, not the estimated number of injections.
    Billing Rule

    Unlisted-Code Review

    Use an unlisted code only when no specific CPT or HCPCS code is available. Unlisted codes are reviewed at the claim level for coverage, medical necessity, correct coding, and pricing.

    • Ensure the unlisted code accurately describes the service and is supported by the medical record.
    • Prior authorization is recommended for potentially covered unlisted services to avoid post-service denial.
    Denial Risk

    Unlisted Code for Non-Covered Service

    An unlisted code submitted for a service that is not covered under this policy will be denied as not covered.

    • Confirm coverage before submitting an unlisted code.
    • Prior authorization does not establish coverage for a non-covered service.
    Billing Rule

    NCCI and MUE Edits Apply

    Submitted HCPCS and CPT codes remain subject to National Correct Coding Initiative procedure-to-procedure bundling edits and CMS medically unlikely edits. This policy does not take precedence over NCCI or MUE requirements.

    • Review applicable NCCI PTP edits and CMS MUE daily maximums.
    • Follow CMS coding guidelines and applicable code combinations.
    Typical duration
    Generally 8 to 28 weeks
    Maintenance Phase
    DefinitionThe SCIT phase after an effective dose is reached, during which injections are maintained at that dosage
    Treatment intervalTypically 2 to 4 weeks between treatments
    Effective doseDepends on the person's response to the build-up phase and degree of allergen sensitivity
    Rapid Desensitization
    Also known asRush, cluster, or acute desensitization
    CPT code95180
    Qualifying pathwaysDrug allergy without effective alternative medications; Hymenoptera insect-sting hypersensitivity; or moderate-to-severe allergic rhinitis requiring seasonal treatment after avoidance or pharmacotherapy failed